Evidence map›Paper›PMID 23689277›Full record

ReviewCell research2013

Sirtuin deacetylases in neurodegenerative diseases of aging.

Adrianna Z Herskovits, Leonard Guarente

Open access · hybridAbstract readReview
In one paragraph

Review in Cell research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 121 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
121citing papers in PubMed, 2 pooled it
10.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

121 citing papers in PubMed, 2 syntheses or guidelines pooled it, 216 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

61 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Adrianna Z HerskovitsDepartment of Pathology, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115, USA.
Leonard Guarente
Brigham and Women's Hospital · USMassachusetts Institute of Technology · US

Funding

MOLECULAR STUDY OF YEAST SGS1 AND RDNA CIRCLES IN AGINGR01AG015339 · NIA · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI GUARENTE, LEONARD P · 1999 to 2014
$5.5M
Cell Senescence in Saccharomyces CerevisiaeR37AG011119 · NIA · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI GUARENTE, LEONARD P · 2002 to 2011
$4.5M
Function in Mammalian SIRT1 in AgingR56AG015339 · NIA · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI GUARENTE, LEONARD P · 2016 to 2016
$230k
NIA NIH HHS R01 AG015339NIA NIH HHS R37 AG011119NIA NIH HHS R56 AG015339
6 · The paper itself

Abstract

Sirtuin enzymes are a family of highly conserved protein deacetylases that depend on nicotinamide adenine dinucleotide (NAD+) for their activity. There are seven sirtuins in mammals and these proteins have been linked with caloric restriction and aging by modulating energy metabolism, genomic stability and stress resistance. Sirtuin enzymes are potential therapeutic targets in a variety of human diseases including cancer, diabetes, inflammatory disorders and neurodegenerative disease. Modulation of sirtuin activity has been shown to impact the course of several aggregate-forming neurodegenerative disorders including Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis and spinal and bulbar muscular atrophy. Sirtuins can influence the progression of neurodegenerative disorders by modulating transcription factor activity and directly deacetylating proteotoxic species. Here, we describe sirtuin protein targets in several aggregate-forming neurodegenerative diseases and discuss the therapeutic potential of compounds that modulate sirtuin activity in these disorders.

Indexed as

Energy MetabolismAgingCaloric RestrictionHistone DeacetylasesHumansNADNeurodegenerative DiseasesSirtuinsHistone DeacetylasesNADSirtuins

Identifiers

PMID23689277
PMCPMC3674397
OpenAlexW2121775361

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.